Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer : a multicenter propensity score-matched analysis
© 2022. The Author(s)..
BACKGROUND: Peri-operative chemo-radiotherapyplayed important rolein locally advanced gastric cancer. Whether preoperative strategy can improve the long-term prognosis compared with postoperative treatment is unclear. The study purpose to compare oncologic outcomes in locally advanced gastric cancer patients treated with preoperative chemo-radiotherapy (pre-CRT) and postoperative chemo-radiotherapy (post-CRT).
METHODS: From January 2009 to April 2019, 222 patients from 2 centers with stage T3/4 and/or N positive gastric cancer who received pre-CRT and post-CRT were included. After propensity score matching (PSM), comparisons of local regional control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) were performed using Kaplan-Meier analysis and log-rank test between pre- and post-CRT groups.
RESULTS: The median follow-up period was 30 months. 120 matched cases were generated for analysis. Three-year LC, DMFS, DFS and OS for pre- vs. post-CRT groups were 93.8% vs. 97.2% (p = 0.244), 78.7% vs. 65.7% (p = 0.017), 74.9% vs. 65.3% (p = 0.042) and 74.4% vs. 61.2% (p = 0.055), respectively. Pre-CRT were significantly associated with DFS in uni- and multi-variate analysis.
CONCLUSION: Preoperative CRT showed advantages of oncologic outcome compared with postoperative CRT.
TRIAL REGISTRATION: ClinicalTrial.gov NCT01291407 , NCT03427684 and NCT04062058 , date of registration: Feb 8, 2011.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC cancer - 22(2022), 1 vom: 26. Feb., Seite 212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Ning [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comparative Study |
|---|
| Anmerkungen: |
Date Completed 17.03.2022 Date Revised 17.03.2022 published: Electronic ClinicalTrials.gov: NCT04062058, NCT03427684, NCT01291407 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-022-09297-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337507732 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337507732 | ||
| 003 | DE-627 | ||
| 005 | 20231225234552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-022-09297-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337507732 | ||
| 035 | |a (NLM)35219300 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Ning |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer |b a multicenter propensity score-matched analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2022 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04062058, NCT03427684, NCT01291407 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Peri-operative chemo-radiotherapyplayed important rolein locally advanced gastric cancer. Whether preoperative strategy can improve the long-term prognosis compared with postoperative treatment is unclear. The study purpose to compare oncologic outcomes in locally advanced gastric cancer patients treated with preoperative chemo-radiotherapy (pre-CRT) and postoperative chemo-radiotherapy (post-CRT) | ||
| 520 | |a METHODS: From January 2009 to April 2019, 222 patients from 2 centers with stage T3/4 and/or N positive gastric cancer who received pre-CRT and post-CRT were included. After propensity score matching (PSM), comparisons of local regional control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) were performed using Kaplan-Meier analysis and log-rank test between pre- and post-CRT groups | ||
| 520 | |a RESULTS: The median follow-up period was 30 months. 120 matched cases were generated for analysis. Three-year LC, DMFS, DFS and OS for pre- vs. post-CRT groups were 93.8% vs. 97.2% (p = 0.244), 78.7% vs. 65.7% (p = 0.017), 74.9% vs. 65.3% (p = 0.042) and 74.4% vs. 61.2% (p = 0.055), respectively. Pre-CRT were significantly associated with DFS in uni- and multi-variate analysis | ||
| 520 | |a CONCLUSION: Preoperative CRT showed advantages of oncologic outcome compared with postoperative CRT | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrial.gov NCT01291407 , NCT03427684 and NCT04062058 , date of registration: Feb 8, 2011 | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a Long-term outcome | |
| 650 | 4 | |a Postoperative chemo-radiotherapy | |
| 650 | 4 | |a Preoperative chemo-radiotherapy | |
| 700 | 1 | |a Xiang, Xiaoyong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Dongbin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chi, Yihebali |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Liming |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jinming |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wenyang |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Ningning |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Shunan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shulian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yueping |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yongwen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yexiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Liyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 22(2022), 1 vom: 26. Feb., Seite 212 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:26 |g month:02 |g pages:212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-022-09297-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 26 |c 02 |h 212 | ||